BeyondSpring Overview

BeyondSpring Pharmaceuticals is a global, clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies. We are advancing our lead asset, an immuno-oncology agent Plinabulin, in a global Phase 3 clinical trial for the reduction of Docetaxel-induced Neutropenia and another Phase 3 clinical trial as an anticancer agent in combination with Docetaxel in advanced non-small cell lung cancer (NSCLC). Plinabulin is also entering Phase 1/2 clinical trials to investigate its therapeutic potential in immuno-oncology. Led by a highly qualified management team with proven pharmaceutical experience and a combined 30+ drugs brought to market, we are well-positioned for expeditious progress to NDA and commercialization.

Learn More

Multiple Phase 3 Pivotal Trials

BeyondSpring Pharmaceuticals is currently evaluating Plinabulin as a second- and third-line treatment for patients with advanced NSCLC and through preventing Neutropenia induced by Docetaxel in NSCLC, Breast cancer, and prostate cancer. Plinabulin has been administered in more than 140 patients to date through now completed Phase 1 and 2 trials in the U.S. and international countries. It has proven to be well-tolerated and has shown encouraging anti-tumor activity. Based on consultation with the U.S. FDA, BeyondSpring is conducting an ongoing single, large global Phase 3 pivotal trial for second- and third-line NSCLC. The global study is taking place in the U.S., other Western countries and China.

Phase 3 NSCLC Trial

Robust Pipeline

BeyondSpring’s lead asset, Plinabulin, works via multiple mechanisms of action to target and alter the tumor microenvironment and disrupt the tumor vasculature. Additionally, we have other promising immuno-oncology drug candidates under pre-clinical development for various cancer indications: BPI-002, an oral small molecule activating T cells, and BPI-003, an oral novel small molecule IKK inhibitor. We obtained a license from the Fred Hutchinson Cancer Research Center (FHCRC) and University of Washington for a broad range platform technology focused on a novel mechanism to inhibit a multitude of oncogenes and previously undruggable targets using small molecules. Through this collaboration, we plan to use our combined resources to screen and optimize potential solutions and use oncology clinical expertise to quickly move these into the clinic for testing.

Learn More